Skip to content
Versanis
  • Science
    • Our Approach
    • Areas of Focus
      • Obesity
      • Heart Failure in Obesity
    • Pipeline
    • Scientific Publications
  • About Us
    • Our Focus
    • Leadership Team
    • Board of Directors
  • News
  • Careers
  • Contact

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

© 2023 Versanis Bio

  • Privacy Policy
  • Terms of Use